← back to search

Sam Thiagalingam

Boston University · US
Area of research
Molecular Biology · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Epigenetics and DNA Methylation, Cardiac Fibrosis and Remodeling, Tryptophan and brain disorders, and Genetic factors in colorectal cancer.
h-index
41
citations
11,048
works
172
NIH funding
primary concept
email

Recent publications

Epigenetics in evolution and adaptation to environmental challenges: pathways for disease prevention and treatment
Epigenomics 2025cited by 15position: lastdoi
The Obesity–Epigenetics–Microbiome Axis: Strategies for Therapeutic Intervention
Nutrients 2025cited by 14position: lastdoi
Therapeutic Horizons: Gut Microbiome, Neuroinflammation, and Epigenetics in Neuropsychiatric Disorders
Cells 2025cited by 12position: lastdoi
The Obesity-Epigenetics-Microbiome Axis: Strategies for Therapeutic Intervention.
2025cited by 8position: contributordoi
Therapeutic Horizons: Gut Microbiome, Neuroinflammation, and Epigenetics in Neuropsychiatric Disorders.
2025cited by 6position: contributordoi
IUPHAR review: Eating disorders, gut microbiota dysbiosis and epigenetic aberrations.
2025cited by 2position: contributordoi
Epigenetics and Gut Microbiota in the Pathogenesis and Treatment of Bipolar Disorder (BD).
2025cited by 1position: contributordoi
Oral-Gut Microbiota Crosstalk and Epigenetic Targets in Metabolic and Neuropsychiatric Diseases.
2025cited by 0position: contributordoi
Potential for New Therapeutic Approaches by Targeting Lactate and pH Mediated Epigenetic Dysregulation in Major Mental Diseases
Biomedicines 2024cited by 12position: lastdoi
Maternal Gut Microbiome-Mediated Epigenetic Modifications in Cognitive Development and Impairments: A New Frontier for Therapeutic Innovation
Nutrients 2024cited by 11position: lastdoi
Epigenome Defines Aberrant Brain Laterality in Major Mental Illnesses
Brain Sciences 2024cited by 9position: lastdoi
Maternal Gut Microbiome-Mediated Epigenetic Modifications in Cognitive Development and Impairments: A New Frontier for Therapeutic Innovation.
2024cited by 8position: contributordoi
Potential for New Therapeutic Approaches by Targeting Lactate and pH Mediated Epigenetic Dysregulation in Major Mental Diseases.
2024cited by 8position: contributordoi
Epigenome Defines Aberrant Brain Laterality in Major Mental Illnesses.
2024cited by 8position: contributordoi
Gut microbiota defined epigenomes of Alzheimer's and Parkinson's diseases reveal novel targets for therapy.
2024cited by 7position: contributordoi
Substance-Induced Psychiatric Disorders, Epigenetic and Microbiome Alterations, and Potential for Therapeutic Interventions.
2024cited by 4position: contributordoi
Epigenetic Aberrations in Major Psychiatric Diseases Related to Diet and Gut Microbiome Alterations
Genes 2023cited by 24position: lastdoi
Epigenetic Alterations of Brain Non-Neuronal Cells in Major Mental Diseases
Genes 2023cited by 23position: lastdoi
Epigenetic Alterations of Brain Non-Neuronal Cells in Major Mental Diseases.
2023cited by 21position: contributordoi
Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies
Genes 2023cited by 20position: lastdoi
Epigenetic Aberrations in Major Psychiatric Diseases Related to Diet and Gut Microbiome Alterations.
2023cited by 16position: contributordoi
Microbiota-Induced Epigenetic Alterations in Depressive Disorders Are Targets for Nutritional and Probiotic Therapies.
2023cited by 16position: contributordoi
Data from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi
Supplementary Figure S1-S10 from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi
Supplementary methods and figure legends from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi
Supplementary Figure S1-S10 from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi
Data from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi
Supplementary Table 1 from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi
Supplementary Table 1 from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi
Supplementary methods and figure legends from Targeting RICTOR Sensitizes SMAD4-Negative Colon Cancer to Irinotecan
2023cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 24 papers (2019–2025) · 20 papers (2020–2025)Hamid M. Abdolmaleky · Boston University16 papers (2014–2025)Shabnam Nohesara · Boston Medical Center10 papers (2014–2025)Jin‐Rong Zhou · Beth Israel Deaconess Medical Center9 papers (2015–2025)Panagiotis Papageorgis · Ministry of Health9 papers (2020–2023)Zaina Sen · 9 papers (2020–2023) · 8 papers (2024–2025)Sait Öztürk · Icahn School of Medicine at Mount Sinai6 papers (2012–2019)Chen Khuan Wong · Memorial Sloan Kettering Cancer Center5 papers (2014–2019)Arthur W. Lambert · AstraZeneca (South Korea)5 papers (2012–2016) · 4 papers (2021–2025)Panagiotis Papageorgis · European University Cyprus4 papers (2015–2019) · 2 papers (2014–2016) · 2 papers (2025–2025)Giuseppe Pettinato · Beth Israel Deaconess Medical Center2 papers (2025–2025) · 2 papers (2014–2015) · 2 papers (2015–2016)Jayant M. Pinto · Chicago Department of Public Health1 papers (2022–2022) · 1 papers (2015–2015)